Updating the influenza virus library at Hokkaido University -It's potential for the use of pandemic vaccine strain candidates and diagnosis

Nomura, Naoki; Matsuno, Keita; Shingai, Masashi; Ohno, Marumi; Sekiya, Toshiki; Omori, Ryosuke; Sakoda, Yoshihiro; Webster, Robert G.; Kida, Hiroshi

doi:10.1016/j.virol.2021.02.005

Cited by 2 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral RNA samples derived from lung homogenates of BXM-treated mice were extracted using a QIAamp® Viral RNA Mini Kit (QIAGEN) according to the manufacturer's protocol. Next-generation sequencing and analysis were then conducted as previously reported [43], after which amino acid substitutions of viruses were detected using the low frequency variant detection method of CLC Genomic Workbench (CLC bio, Aarhus, Denmark). Sequencing coverage for variant detection of this test was more than 10-fold depth, and the percentage of reads with a quality score greater than 30 was 70%.…”

Section: Methodsmentioning

confidence: 99%

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against the H5 Highly Pathogenic Avian Influenza Virus Infection

Taniguchi¹,

Ando²,

Kobayashi³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Human infections with the H5 highly pathogenic avian influenza virus (HPAIV) sporadically threatens public health. The susceptibility of HPAIVs to baloxavir acid (BXA), which is a new class of inhibitor for the influenza virus cap-dependent endonuclease, has been confirmed in vitro, but has not yet been characterized fully. Here, the efficacy of BXA against HPAIVs, including recent H5N8 variants in vitro was assessed. The antiviral efficacy of baloxavir marboxil (BXM) in H5N1 virus-infected mice was also investigated. BXA exhibited similar in vitro activities against H5N1, H5N6, and H5N8 variants tested to those of seasonal and other zoonotic strains. BXM monotherapy in mice infected with the H5N1 HPAIV clinical isolate; A/Hong Kong/483/1997 (H5N1) strain, also caused a significant reduction in viral titers in the lungs, brains, and kidneys, followed by prevention of acute lung inflammation and improvement of mortality compared with oseltamivir phosphate (OSP). Furthermore, combination treatments with BXM and OSP, using a 48-hour delayed treatment model showed a more potent effect on viral replication in organs, accompanied by improved survival compared to BXM or OSP monotherapy. From each test, no resistant virus (e.g., I38T in the PA) emerged in any BXM-treated mouse. These results therefore support the conclusion that BXM has potent antiviral efficacy against H5 HPAIV infections.

show abstract

Section: Methodsmentioning

confidence: 99%

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against the H5 Highly Pathogenic Avian Influenza Virus Infection

Taniguchi¹,

Ando²,

Kobayashi³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, it is necessary to select the strains that will be prevalent in the next season at an early stage, and the prediction may be in error. In contrast, we are in the process of selecting vaccine strains to accommodate any subtype of influenza virus by establishing an influenza virus library that contains 4580 strains [ 174 ]. This strategy, though not yet global, can make a significant contribution to vaccine preparation and the diagnosis of future pandemic influenza viruses.…”

Section: Current Challenges For Controlling the Pandemic Respiratory Virusesmentioning

confidence: 99%

Strategies for fighting pandemic virus infections: Integration of virology and drug delivery

Nakamura

Isoda

Sakoda

et al. 2022

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

Respiratory viruses have sometimes resulted in worldwide pandemics, with the influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being major participants. Long-term efforts have made it possible to control the influenza virus, but seasonal influenza continues to take many lives each year, and a pandemic influenza virus sometimes emerges. Although vaccines for coronavirus disease 2019 (COVID-19) have been developed, we are not yet able to coexist with the SARS-CoV-2. To overcome such viruses, it is necessary to obtain knowledge about international surveillance systems, virology, ecology and to determine that immune responses are effective. The information must then be transferred to drugs. Delivery systems would be expected to contribute to the rational development of drugs. In this review, virologist and drug delivery system (DDS) researchers discuss drug delivery strategies, especially the use of lipid-based nanocarriers, for fighting to respiratory virus infections.

show abstract

Updating the influenza virus library at Hokkaido University -It's potential for the use of pandemic vaccine strain candidates and diagnosis

Cited by 2 publications

References 65 publications

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against the H5 Highly Pathogenic Avian Influenza Virus Infection

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against the H5 Highly Pathogenic Avian Influenza Virus Infection

Strategies for fighting pandemic virus infections: Integration of virology and drug delivery

Contact Info

Product

Resources

About